drugset
drugset / Trial / NCT01917617

Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer

NCT01917617 ↗

Phase 2 Completed 50 enrolled Kansai Hepatobiliary Oncology Group
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and feasibility of oral rehydration therapy for short hydration in patients with biliary tract cancer who will undergo the chemotherapy including gemcitabine and cisplatin.

Timeline

Start
2013-05-22
Primary completion
2016-01-07
Completion
2016-07-07

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified 25 mg/m2 Intravenous
Background Gemcitabine Small molecule — Intravenous

Indications

biliary tract cancer